Authors
Kolcov A.V., Kalimulin O.A., Kachnov V.A., Greckaya E.V., SHCHerbatyuk O.V., Tyrenko V.V., Alekseev A.N., Svistov A.S.
Military medical Academy named after S.M. Kirov, Saint-Petersburg
Abstract
A study was conducted to assess the clinical efficacy and impact on the quality of life of valsartan+sacubitril therapy in patients with chronic heart failure and chronic obstructive pulmonary disease. 52 patients were examined. The examined patients were divided into two groups: 27 patients were included in group 1 and 25 in group 2. For the correction of the manifestations of chronic heart failure and assessing the effectiveness of patients of the 1st group were administered valsartan, patients of group 2 – a combination of valsartan+sacubitril. All patients included in the study were examined initially at the time of inclusion in the study, on 10 and 30 days from the date of hospitalization. The final examination was conducted 6 months after hospitalization. All patients underwent a comprehensive examination of the respiratory and circulatory systems. All patients filled in the scale of clinical condition (ШОКС) (modification of Mareev V.U., 2000), “questionnaire for patients with respiratory diseases of St. George’s hospital” (SGRQ) and questionnaire 12_EQ-5D-5L. According to the results of the study, in both groups there was a positive dynamics in the form of leveling the manifestations of chronic heart failure, but in the combination of factors we can talk about a more significant clinical effect in group 2, taking a combination of valsartan+sacubitril. So for the control period of time there were no deaths, repeated hospitalization for decompensation of chronic heart failure, there was a better dynamics in the parameters of mobility and habitual/daily activities, there was a more rapid onset of clinical effect. In the analysis (1 group n = 12; 2 group n = 15) after 6 months in group 2, there was a significantly lower number of repeated hospitalizations due to decompensation of CHF – 6 from group 1, 1 from group 2,a significantly greater degree of reduction of NT-proBNP (p<0,05) and a significant increase of LV EF (p<0,05).
Keywords: heart failure, chronic obstructive pulmonary disease, comorbidity, valsartan, sacubitril, quality of life.
References
1. Mareev VU, Fomin IV, Ageev FT, Arutyunov GP, Begrambekova UL, Belenkov UN. Klinicheskie rekomendacii. Hronicheskaya serdechnaya nedostatochnost (HSN) // Serdechnaya Nedostatochnost. – 2017. – № 18(1). – S. 3–40. (In Russ).
2. Chuchalin AG, Avdeev SN, Ajsanov ZR. Rossijskoe respiratornoe obshchestvo. federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu hronicheskoj obstruktivnoj bolezni legkih // Pulmonologiya. – 2014. – № 3. – S. 15–54. (In Russ).
3. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease // Chest – 2005. – № 128(5). – P. 3618–3624.
4. Assayag P. Alteration of the alveolar-capillary membrane diffusing capacity chronic left heart disease // Am. J. Cardiol. – 1998. –№ 82(4). – P. 459–464.
5. Burgel PR, Mannino D. Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease //American Journal of Respiratory and Critical Care Medicine – 2012. – № 186(10). – P. 936–937.
6. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD // Eur. Respir. J. – 2008. – № 32(5). – P. 1371–1385.
7. Doehner W. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review // Wien Klin. Wochenschr. – 2009. – № 121(9). – P. 293–296.
8. Lam CS. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community // Circulation – 2011. – № 124(1). – P. 24–30.
9. Lu Y. Systemic inflammation, depression and obstructive pulmonary function: a population-based study // Respiratory Research – 2013. – № 14(1). – 53 р.
10. Miller J. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort // Respiratory medicine – 2013. – № 107(9). – P. 1376–1384.
11. Pandey A, Clarus S, Pandey A, Verma S. The impact of arni therapy on lv systolic function as measured by 2-d echocardiography: a 1 year case series // Canadian Journal of Cardiology. – 2017. – Vol. 33(10). – Р. 161–162.
12. Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD // Chest – 2008. – № 134(4). – P. 808–814.
13. Rutten FH. Diagnosis and management of heart failure in COPD, in COPD and Comorbidity // European Respiratory Society Journals Ltd. – 2013. – № 59. – P. 50–63.
14. Sabit R. Sub-clinical left and right ventricular dysfunction in patients with COPD // Respir. Med. – 2010. – № 104(8). – P. 1171–1178.
15 Shujaat A, Bajwa AA, Cury JD. Pulmonary Hypertension Secondary to COPD // Pulm. Med.– 2012. – Article ID 203952. – 16 p.
16. van Deursen VM. Co-morbidities in heart failure // Heart Fail. Rev. – 2012. – № 16. – P. 103–111.
17. van Gestel AJ, Kohler M, Clarenbach CF. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD) // Discov. Med. – 2012. – № 14(79). – P. 359–368.
18. Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: The vascular story // Pulm. Circ. – 2011. – № 1(3). – Р. 320–326.
19. Weitzenblum E, Chaouat A. Cor pulmonale // Chron. Respir. Dis. – 2009. – № 6(3). – Р. 177–185.
20. Weitzenblum E. Chronic cor pulmonale // Heart. – 2003. – № 89(2). – Р. 225–230.
